Shankar Siva· @_ShankarSiva · X·· 1 day agoScore70
Body · original
#ESMO26 @tompowles1 presents at the 👑presidential 👑 session VOLGA n=1009 phIII neoadjuvant #bladdercancer trial. 24mo EFS 63.5% vs 45% (HR 0.51), pCR 45% vs 10%. Triplet +tremelimumab hits EFS but not yet OS. #MIBC - @NEJM paper ➡️ ➡️ https://shorturl.at/7cyc9
146 views · 2 likes · 2 reposts · 0 replies
Conference abstracts
LBA2matched by Presidential Symposium I
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgSource: Shankar Siva · x.com